The Administrative Core will support and facilitate the translational research that is described in the Yale Autoimmunity Center of Excellence. The following Aims are proposed for the Core:
Specific Aim 1 : To perform the administrative tasks for the Yale ACE. The Core will arrange the monthly meetings of the ACE and the meetings of the Executive Committee. The Core will also provide support to fulfill the local regulatory requirements for clinical trials, and where needed, animal protocols.
Specific Aim 2 : To facilitate interactions among all of the participating clincical investigators. The Core will provide the regulatory support needed for approval of clinical trials at sites off the Yale campus. Samples that are shared between sites will be managed by the Core.
Specific Aim 3 : To establish a recruitment "team" for clinical trials. A research coordinator will be supported by the Administrative Core. This individual will interact closely with the Yale Center for Clinical Investigation and use resources that are available from the CTSA to help with clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082713-04
Application #
8375231
Study Section
Special Emphasis Panel (ZAI1-QV-I)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
4
Fiscal Year
2012
Total Cost
$140,850
Indirect Cost
$69,752
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Cantaert, Tineke; Schickel, Jean-Nicolas; Bannock, Jason M et al. (2016) Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint. J Clin Invest 126:4289-4302
Tooley, James E; Vudattu, Nalini; Choi, Jinmyung et al. (2016) Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol 46:230-41
Chamberlain, Nicolas; Massad, Christopher; Oe, Tyler et al. (2016) Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest 126:282-7
Romberg, Neil; Virdee, Manmeet; Chamberlain, Nicolas et al. (2015) TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development. J Allergy Clin Immunol 136:1315-25
Cantaert, Tineke; Schickel, Jean-Nicolas; Bannock, Jason M et al. (2015) Activation-Induced Cytidine Deaminase Expression in Human B Cell Precursors Is Essential for Central B Cell Tolerance. Immunity 43:884-95
Berkowska, Magdalena A; Schickel, Jean-Nicolas; Grosserichter-Wagener, Christina et al. (2015) Circulating Human CD27-IgA+ Memory B Cells Recognize Bacteria with Polyreactive Igs. J Immunol 195:1417-26
Pala, Francesca; Morbach, Henner; Castiello, Maria Carmina et al. (2015) Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. J Clin Invest 125:3941-51
Sehgal, Kartik; Ragheb, Ragy; Fahmy, Tarek M et al. (2014) Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol 193:2297-305
Ruddle, Nancy H (2014) Lymphotoxin and TNF: how it all began-a tribute to the travelers. Cytokine Growth Factor Rev 25:83-9
Lee, Naeun; You, Sungyong; Shin, Min Sun et al. (2014) IL-6 receptor α defines effector memory CD8+ T cells producing Th2 cytokines and expanding in asthma. Am J Respir Crit Care Med 190:1383-94

Showing the most recent 10 out of 63 publications